UK Health Security Agency. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 35: UKHSA; 2022[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1050999/Technical-Briefing-35-28January2022pdf
Hui KPY, Ho JCW, Cheung Mc, Ng Kc, Ching RHH, Lai Kl et al. Replication of the SARS-CoV-2 Omicron variant in human bronchi and lung ex vivo. temper nature. 2022; 603 (7902): 715-20.
UK Health Security Agency. COVID-19 Vaccine Surveillance Report Week 6 2022[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6PDF[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6بيديإف[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1054071/vaccine-surveillance-report-week-6pdf
Rössler A, Knabl L, Laer Dv, Kimpel J. Neutralization profile of diverse convalescent individuals in Omicron. medRxiv. 2022: 2022.02.01.22270263.
Al-Tarawneh H, Schmitli H, Hassan Murr, Ayoub H, Qassem S, Miqdad, et al. Protection against the Omicron variant of previous SARS-CoV-2 infection. In Engel J Med. 2022.
European Center for Disease Prevention and Control. Assessment of the additional prevalence and potential impact of the omicron variant SARS-CoV-2 of concern in the EU/EEA, 19th update 2022[availablefrom:https://wwwecdceuropaeu/sites/default/files/documentation/RRA-19-update-27-jan-2022pdf[Availablefrom:https://wwwecdceuropaeu/sites/default/files/documents/RRA-19-update-27-jan-2022pdf[متاحمن:https://wwwecdceuropaeu/sites/default/files/الوثائق/RRA-19-update-27-jan-2022pdf[Availablefrom:https://wwwecdceuropaeu/sites/default/files/documents/RRA-19-update-27-jan-2022pdf
Faria NR, Mellan TA, Whittaker C, Clear IM, Candido DdS, Mishra S et al. Genomics and epidemiology of the P.1 SARS-CoV-2 strain in Manaus, Brazil. Sciences. 2021.
UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing: Update on Hospitalization and Vaccine Efficacy for Omicron VOC-21NOV01 (B.1.1.529) UKHSA; 2021[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_updatepdf
Lyngse FP, Kirkeby CT, Denwood M, Christianen LE, Mølbak K, Møller CH, et al. Transmission of SARS-CoV-2 Omicron VOC sub variants BA.1 and BA.2: evidence from Danish families. medRxiv. 2022: 2022.01.28.22270044.
Fonager J, Bennedbæk M, Bager P, Wohlfahrt J, Ellegaard KM, Ingham AC, et al. Molecular epidemiology of the substrain of the SARS-CoV-2 variant Omicron BA.2 in Denmark, November 29, 2021 to January 2, 2022. Eurosurveillance. 2022; 27 (10): 2
UK Health Security Agency (UKHSA). SARS-CoV-2 variants of concern and variants under investigation in England – Technical Briefing 39: UKHSA; 2022[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINALpdf
Khan K, Karim F, Ganga Y, Bernstein M, Jules Z, Redoy K, et al. Omicron substrains BA.4/BA.5 escaping BA.1 elicited neutralizing immunity. medRxiv. 2022: 2022.04.29.22274477.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L et al. Antibodies caused by omicron infection BA.2.12.1, BA.4 and BA.5. bioRxiv. 2022: 2022.04.30.489997.
Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and effect of the SARS-CoV-2 B.1.1.7 strain in England. Sciences. 2021; 372.
Davies NG, Jarvis CI, van Zandvoort K, Clifford S, Sun FY, Funk S et al. Increased mortality in community-tested cases of SARS-CoV-2 B.1.1.7. temper nature. 2021.
Funk T, Pharris A, Spiteri G, Bundle N, Melido A, Carr M et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. European monitoring. 2021; 26 (16): 2100348.
Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et al. The SARS-CoV-2 spike E484K mutation reduces the neutralization of the antibody. Lancet microbe.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine antibodies. temper nature. 2021.
Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK et al. Transmission and inactivation of an antibody to an emerging variant of SARS-CoV-2 in California carrying the L452R protein mutation. medRxiv. 2021.
French public health. New variant discovered and under surveillance in Brittany 2021[updatedon16-03-2021Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detect-et-sous-surveillance-en-bretagne[updated2021-03-16Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detecte-et-sous-surveillance-en-bretagne[تمالتحديثفي2021-03-16متاحمن:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detect-et-sous-surveillance-en-bretagne[updated2021-03-16Availablefrom:https://wwwsantepubliquefrancefr/presse/2021/nouveau-variant-detecte-et-sous-surveillance-en-bretagne
Shu Y, McCauley J. GISAID: A global initiative to share all influenza data–from vision to reality. European monitoring. 2017; 22 (13): 30494.
Zhao X, Zheng A, Li D, Zhang R, Sun H, Wang Q et al. Anti-ZF2001 neutralization of SARS-CoV-2 variants. Lancet microbe. 2021.
England PH. SARS-CoV-2 variants of concern and variants under investigation in England. Technical Briefing 11 2021[Available:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[Availablefrom:https://assetspublishingserviceloadsgov/uploads/system/uptach_98]/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/986380/Variants_of_Concern_VOC_Technical_Briefing_11_Englandpdf
Tut G, Lancaster T, Krutikov M, Sylla P, Bone D, Kaur N et al. Profile of humoral and cellular immune responses to a single BNT162b2 or ChAdOx1 vaccine in residents and staff within residential care homes (VIVALDI Study). Preprints with The Lancet 2021.
Tada T, Chu H, Dacosta BM, Samanovic ME, Mulligan MG, Landau NR. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India confer partial resistance to vaccine-generated therapeutic monoclonal antibodies. bioRxiv. 2021.
Hoffmann M, Hoffmann-Winckler H, Krueger N, Kempf A, Nihlmayer I, Gration L, et al. The B.1.617 SARS-CoV-2 variant is resistant to Bamlanivimab and avoids antibodies caused by infection and vaccination. bioRxiv. 2021.
Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY et al. Neutralization of the variant under consideration B.1.617 with BBV152 vaccine serum. bioRxiv. 2021.
Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, et al. Identification of SARS-CoV-2 mutations that attenuate neutralization of monoclonal antibodies and serum. Host cell and microbe. 2021; 29 (3): 477-88.e4.
Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. The detection of SARS-CoV-2 is of concern in South Africa. temper nature. 2021; 592 (7854): 438-43.
Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G et al. SARS-CoV-2 501Y.V2 escape from neutralization by convalescent plasma. temper nature. 2021.
Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New England Journal of Medicine. 2021.
Pearson California. Estimates of severity and transmission of the novel SARS-CoV-2 variant in South Africa 501Y.V2[Availablefrom:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[Availablefrom:https://covid/covid19]/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[متاحمن:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf[Availablefrom:https://cmmidgithubio/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SApdf
Greeny AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor binding domain that affect the recognition of polyclonal human plasma antibodies. Host cell and microbe. 2021; 29 (3): 463-76.e6.
Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. Effect of B.1.1.7 variant mutations on SARS-CoV-2 linear epitope antibody recognition. medRxiv. 2021: 2021.01.06.20248960.
Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. bioRxiv. 2020.
Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et al. Infection and immune escape of a novel SARS-CoV-2 variant from Lambda. medRxiv. 2021.
Tada T, Chu H, Dacosta BM, Samanovic ME, Mulligan MG, Landau NR. The SARS-CoV-2 Lambda variant remains susceptible to neutralization by antibodies extracted from vaccine mRNA and convalescent serum. bioRxiv. 2021.
UK Health Security Agency. SARS-CoV-2 Variants of Concern and Variants Under Investigation in England (Technical Briefing 27) 2021[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/Technical-briefing-27pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27pdf[متاحمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/Technical-briefing-27pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/1029715/technical-briefing-27pdf
Lassauniere R, Polacek C, Fonager J, Bennedbaek M, Boding L, Rasmussen M et al. Neutralization of the SARS-CoV-2 Delta substrain AY.4.2 and B.1.617.2 + E484K by sera from BNT162b2 mRNA vaccine. medRxiv. 2021: 2021.11.08.21266075.
Dejnirattisai W, Zhou D, Supasa P, Liu C, Mentzer AJ, Ginn HM et al. The antibody is evaded by the P.1 strain of SARS-CoV-2. cell. 2021
Public Health England. SARS-CoV-2 Variants of Concern and Variables Under Investigation in England Technical Brief 12 2021[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[Availukpublishing:https://assetspublishfrom:government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[متوفرمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/988619/Variants_of_Concern_VOC_Technical_Briefing_12_Englandpdf
Jimmy Lopez Bernal NA, Charlotte Gower, Ellen Gallagher, Dr. Zambon, Kevin Brown, Susan Hopkins, Mira Chand, Mary Ramsay. Efficacy of COVID-19 vaccines against B.1.617.2 2021 variant[Availablefrom:https://khubnet/documents/135939561/42+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[Availablefrom:https://khubnet/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+the+B16172+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[متاحمن:https://khubnet/documents/135939561/42+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42[Availablefrom:https://khubnet/documents/135939561/430986542/Effectiveness+of+COVID-19+vaccines+against+the+B16172+variantpdf/204c11a4-e02e-11f2-db19-b3664107ac42
Sheikh A, McMenamin C, Taylor B, Robertson C. SARS-CoV-2 delta VOCs in Scotland: demographics, risk of hospitalization, and vaccine efficacy. scalpel;
Stowe J, Andrews N, Gower C, Gallagher E, Otsy L, Simmons R, et al. Efficacy of COVID-19 vaccines against hospitalization with delta variant (B.1.617.2) 2021[availablefrom:https://khubnet/documents/135939561/479607266/Effectivity+of+COVID-19+vaccines+against+hospital+with+delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431[Availablefrom:https://khubnet/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against++admission+with+the+Delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431[متوفرمن:https://khubnet/documents/135939561/479607266/Effectivity+of+COVID-19+vaccines+against+دخولالمستشفى+مع+دلتا+٪28B16172٪29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997؟t=1623689315431[Availablefrom:https://khubnet/documents/135939561/479607266/Effectiveness+of+COVID-19+vaccines+against+hospital+admission+with+the+Delta+%28B16172%29+variantpdf/1c213463-3997-ed16-2a6f-14e5deb0b997?t=1623689315431
Public Health England. SARS-CoV-2 Variants of Concern and Variables Under Investigation in England Technical Brief 16 2021[availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[Availablepublishfrom:https://servicespublishing:https://servicespublishinggovernment/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[متوفرمن:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf[Availablefrom:https://assetspublishingservicegovuk/government/uploads/system/uploads/attachment_data/file/997414/Variants_of_Concern_VOC_Technical_Briefing_16pdf